Intellectual Property

Silenseed holds and develops an extensive IP portfolio, which currently encompasses seven families of patents in process. Our portfolio covers many aspects of RNAi-based treatments, including targets, delivery, and modalities, which assists us on our way to commercializing RNAi therapeutics. Granted (issued) patents:
US 9,764,035 B2 “Methods and composition for treating prostate cancer”
US 9,687,500 “Methods and compositions for treating cancer”
US 8,889,642 “Methods and compositions for RNAi-based cancer treatment”
US 8,999,945 “Methods, compositions and systems for local delivery of drugs”
US 9,006,199 “Methods and compositions for treating prostate cancer”
US 9,080,173 “Methods and compositions for RNAi-based cancer treatment” (divisional, composition of matter)
US 10,006,030 “RNA interference compositions targeting heat shock protein 90 and methods of use thereof”
EP 2,323,630 “METHODS, COMPOSITIONS AND SYSTEMS FOR LOCAL DELIVERY OF DRUGS”
EP 2,591,770 “Compositions for siRNA delivery and methods of manufacturing and using same”